Giovanni Orsolini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9153531/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Correspondence on a€ Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryâ€ [™] by Gianfrancesco <i>et al</i>). Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 second the rheumatic musculoskeletal diseases. Annals of the Rheumatic	0.5	4
2	Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study. RMD Open, 2022, 8, e002055.	1.8	29
3	Antiâ€phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an allâ€comer population. Journal of Thrombosis and Haemostasis, 2022, 20, 2070-2074.	1.9	9
4	Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211050.	1.2	2
5	Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. Internal and Emergency Medicine, 2021, 16, 863-874.	1.0	5
6	Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1386-1388.	2.0	21
7	Association between environmental air pollution and rheumatoid arthritis flares. Rheumatology, 2021, 60, 4591-4597.	0.9	43
8	Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2021, 24, 510-518.	0.9	0
9	The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases. Arthritis Research and Therapy, 2021, 23, 89.	1.6	0
10	Bone Marrow Mastocytosis: A Diagnostic Challenge. Journal of Clinical Medicine, 2021, 10, 1420.	1.0	12
11	The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders. Frontiers in Endocrinology, 2021, 12, 620920.	1.5	18
12	Sex-Specific Association of Left Ventricular Hypertrophy With Rheumatoid Arthritis. Frontiers in Cardiovascular Medicine, 2021, 8, 676076.	1.1	3
13	Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis. Arthritis Research and Therapy, 2021, 23, 158.	1.6	4
14	Environmental Air Pollution Is a Predictor of Poor Response to Biological Drugs in Chronic Inflammatory Arthritides. ACR Open Rheumatology, 2021, 3, 451-456.	0.9	13
15	Immunoglobulin G4-Related Disease Responder Index Correlates With the Risk of 1-Year Relapse in Type 1 Autoimmune Pancreatitis. Pancreas, 2021, 50, 879-881.	0.5	5
16	Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?― Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2943-2944.	2.0	2
17	SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021068.	0.5	13
18	Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study. Clinical and Experimental Rheumatology, 2021, 39, 344-350.	0.4	0

GIOVANNI ORSOLINI

#	Article	IF	CITATIONS
19	A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years' Experience of the GISM Network. Cancers, 2021, 13, 6380.	1.7	16
20	Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study. Clinical and Experimental Rheumatology, 2021, 39, 344-350.	0.4	1
21	Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al. Annals of the Rheumatic Diseases, 2020, 79, e166-e166.	0.5	4
22	Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations. Annals of the Rheumatic Diseases, 2020, 79, e150-e150.	0.5	7
23	Usefulness of CHA2DS2â€VASc score to predict mortality and hospitalization in patients with inflammatory arthritis. International Journal of Rheumatic Diseases, 2020, 23, 106-115.	0.9	2
24	Could Previous Exposure to Nitrogen ontaining Bisphosphonates Mitigate Friendly Fire?. Journal of Bone and Mineral Research, 2020, 35, 2082-2082.	3.1	2
25	Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment. Frontiers in Medicine, 2020, 7, 613720.	1.2	18
26	Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement. Clinical Rheumatology, 2020, 39, 727-736.	1.0	8
27	Incidence and predictors of adverse clinical events in patients with rheumatoid arthritis and asymptomatic left ventricular systolic dysfunction. Clinical and Experimental Rheumatology, 2020, 38, 420-427.	0.4	1
28	Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis. Pharmacological Research, 2019, 147, 104354.	3.1	30
29	Vitamin D serum levels and the risk of digital ulcers in systemic sclerosis: A longitudinal study. International Journal of Rheumatic Diseases, 2019, 22, 1041-1045.	0.9	13
30	FRIO469â€CHANGES IN DKK-1, SCLEROSTIN, AND RANKL SERUM LEVELS FOLLOWING DISCONTINUATION OF LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN. , 2019, , .		0
31	OP0230â€EFFECTIVENESS OF INFLUENZA VACCINE IN TNF INHIBITORS TREATED PATIENTS. , 2019, , .		0
32	FRIO045â€CHANGES IN LEFT VENTRICULAR SYSTOLIC FUNCTION ARE PREDICTED BY DISEASE SEVERITY IN PATIENTS WITH RHEUMATOID ARTHRITISWITHOUT PRIOR CARDIOVASCULAR DISEASE. , 2019, , .		0
33	AB0641â€VITAMIN D SERUM LEVELS AND THE RISK OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A LONGITUDINAL STUDY. , 2019, , .		0
34	Osteoporosis in Rheumatic Diseases. International Journal of Molecular Sciences, 2019, 20, 5867.	1.8	76
35	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. Cancers, 2019, 11, 30.	1.7	7
36	An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. Modern Rheumatology, 2019, 29, 1059-1062.	0.9	25

GIOVANNI ORSOLINI

#	Article	IF	CITATIONS
37	Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells. Journal of Bone and Mineral Research, 2019, 34, 570-571.	3.1	7
38	Anti-CCP antibodies and bone. Arthritis Research and Therapy, 2018, 20, 63.	1.6	3
39	Rheumatoid arthritis, γδT cells and bisphosphonates. Annals of the Rheumatic Diseases, 2018, 77, e57-e57.	0.5	5
40	Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. Arthritis Research and Therapy, 2018, 20, 233.	1.6	2
41	Bone Disease in Mastocytosis. Immunology and Allergy Clinics of North America, 2018, 38, 443-454.	0.7	25
42	Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. Clinical Rheumatology, 2018, 37, 3093-3098.	1.0	16
43	Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients. Calcified Tissue International, 2017, 101, 17-23.	1.5	52
44	Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series. Calcified Tissue International, 2017, 100, 595-598.	1.5	26
45	Cardiovascular morbidity and mortality in patients with rheumatic disease: hyperuricemia, a forgotten puzzle piece?. Clinical Rheumatology, 2017, 36, 2869-2870.	1.0	0
46	Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease. Clinical Rheumatology, 2017, 36, 2487-2495.	1.0	11
47	Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis?. Journal of Bone and Mineral Research, 2017, 32, 2142-2143.	3.1	14
48	Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness. European Journal of Preventive Cardiology, 2016, 23, 1848-1859.	0.8	16
49	Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. Bone, 2016, 92, 150-156.	1.4	40
50	Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis. Calcified Tissue International, 2016, 99, 360-364.	1.5	39
51	Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis. Calcified Tissue International, 2016, 98, 580-585.	1.5	21
52	Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. Rheumatology International, 2015, 35, 255-263.	1.5	34
53	Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. Endocrine, 2015, 49, 620-627.	1.1	14
54	In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clinical and Experimental Rheumatology, 2015, 33, 77-83.	0.4	50

#	Article	IF	CITATIONS
55	Zoledronic Acid in Osteoporosis Secondary toÂMastocytosis. American Journal of Medicine, 2014, 127, 1127.e1-1127.e4.	0.6	31
56	Bone Involvement and Osteoporosis in Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 383-396.	0.7	72
57	Is there Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Real-World Paired Serum and Plasma Testing. Thrombosis and Haemostasis, 0, , .	1.8	0